Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228390 · ClinicalTrials.gov registry record · Phase 2
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 4
- Study locations
NCT07228390: Recruiting Phase 2 study of Hidradenitis Suppurativa, sponsored by Pfizer.
NCT07228390 is a Phase 2 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Pfizer. The registered enrollment target is 240 participants, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228390, a Phase 2 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * have moderate or severe HS * have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose. Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone. The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.
Primary Outcome
The difference in proportion of responders based on HiSCR50 response at Week 16 in patients with HS treated with ritlecitinib versus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritlecitinib
Study Locations (4)
California
- Northridge Clinical Trials - Northridge
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Michigan
- Revival Research Institute, LLC - Troy
Ohio
- ClinOhio Research Services - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2027-04-02 |
| Phase | Phase 2 |
What NCT07228390 shows while recruiting
NCT07228390 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07228390 reports a single indexed study location in California, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT07228390 about?
NCT07228390 is a clinical study titled "A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.". The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * have moderate or severe...
What is the current status of trial NCT07228390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-11-13. Estimated completion is 2027-04-02.
What conditions does trial NCT07228390 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07228390?
The interventions under investigation include: Placebo (DRUG), Ritlecitinib (DRUG).
Who is sponsoring clinical trial NCT07228390?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228390 being conducted?
This trial has 4 study locations across California, Indiana, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228390's enrollment target sits among peer trials
240 20th of 52 higher than 33 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI